Home / Transcripts / Mold-Tek Packaging Limited (533080) · May 11, 2026

Mold-Tek Packaging Limited (533080) Earnings Call Transcript

May 11, 2026

BSE Limited IN Materials Containers and Packaging earnings 62 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the Moltech Packaging Limited Q4FY26 earnings conference call, hosted by MK Global Financial Services Limited. Please be reminded that every participant line is in listen-only mode, and after the presentation wraps up there will be an opportunity for you to ask questions. If you need assistance at any point during this conference call, please signal an operator by pressing Star then 0 on your Touchstone 4. We'd like to note that this conference is being recorded. I'll now hand the conference over to Mr. Rajesh Kumar from MK Global Financial Service. Thank you, and over to you, Mr. Kumar.

Rajesh Kumar Gupta analyst
#2

Good afternoon, everyone. I'd like to welcome Mr. J. Lakshman Rao, our Chairman and Managing Director, and thank him for giving us this opportunity. I'll now turn the call over to him for his opening remarks. Over to you, sir.

Janumahanti Lakshmana Rao executive
#3

Good afternoon, everyone. Thanks so much for joining our conference call on quarterly and annual earnings. I'm delighted to report strong results from Maltech Packaging — every unit is running at better capacity utilization than before, and in particular, merging five Hyderabad facilities into two, namely Unit 1 and 10, has boosted overall performance and efficiencies and produced improved EBITDA margins, and that will continue going forward. Also, another notable item this quarter is pharma packaging. It grew 37% compared with Q4 of last year, and full-year growth came in above 200%, which gives us the ability to target higher numbers ahead. We're also broadening our product range in Pharma and have ideas for adding some odd lines of activity in pharma that can turn the Multec into a decent major player in this segment. So going forward, the paints business, especially on the paint side, has posted double digit growth this year. That is one of the reasons we are closing the year at around 13% sales growth, 13.4%, and although there is a disappointing trend in Loop's segment, it was well offset by more than 15% growth in food and FMCV and Qpex 25% and of course pharma 200%, overall resulting in a healthy 13.4% growth.

Janumahanti Lakshmana Rao executive
#4

I'd prefer to go into further detail during the question-and-answer portion. I owe it to the operator to get the Q&A session started.

Operator operator
#5

Thank you so much. We'll move into the Q&A portion at this point. If you'd like to pose a question, you can press RN1 on your Touchstone phone. Should you want to drop out of the queue, just press 2. We ask that everyone use their handsets when asking a question. Ladies and gentlemen, we'll pause briefly while the queue builds up. Participants, you may press star and one to ask the question. Our first question comes from Sanmar Jain <<inaudible>> of Kamayakia Wealth Management. Please go ahead. Yes, my voice is sounding muffled. Could you speak through the handset, please?

Sanmat Jain analyst
#6

Yeah. Is everything fine at this point?

Operator operator
#7

Yeah, a little bit better.

Sanmat Jain analyst
#8

Yes. Thanks for giving me the chance to ask. My question is about the partnership with Vibe. Did that contract bring in any revenue during Q4?

Janumahanti Lakshmana Rao executive
#9

Yes. I noted on my earlier con call that this represents a long-term opportunity, with us collaborating with Vibe on creating a fresh range of products—particularly closures aimed at high-end chemicals and lubricants. And at this point, two of the three products—they've provided the designs to us; for those two products, the pilot moulds are ready. However, for these molds to turn commercial and begin contributing revenues, it will definitely take another two or three quarters. So the numbers should start showing up around the close of this financial year—26, 27. So as of now it remains at the developmental stage, though among the products we're bringing out, two of the three have already succeeded in pilot trials. And greater visibility would emerge only following a couple of quarters.

Sanmat Jain analyst
#10

So you provided us with guidance of 55 to 60,000 pharma for FY27. Does that figure include this contract revenue, or would it come on top of that?

Janumahanti Lakshmana Rao executive
#11

For the upcoming full financial year, our goal is 55 crores. In 26 and 27, we reached 35 — actually 34.4 crores this financial year. So we've assumed 50% growth. That puts us somewhere near the range of 50 to 55 crores for Pharma. I hope we're on track for that.

Sanmat Jain analyst
#12

Alright. Alright, thanks. That's all from us.

Operator operator
#13

Thanks. Our next question comes from Richa with Equity Master. Your line is open.

Richa Agarwal analyst
#14

Hey there, can everyone hear me okay?

Operator operator
#15

Yes.

Richa Agarwal analyst
#16

Thanks for letting me ask. Sir, would you be able to break out the volume growth in the paint segment — you know, both with calcium and without gassing?

Janumahanti Lakshmana Rao executive
#17

Right, both with Grassim and without Grassim. I don't have those figures right in front of me, but Grassim has made a handsome contribution to paint growth, since they've been the sort of new entrants whose numbers are growing faster. So volume in ABG has also jumped by over 60% versus the prior year, because last year's base was much smaller. At present the numbers keep improving each month or each quarter. So they're contributing handsomely, and they sit in the top 10 supply. I mean,

Richa Agarwal analyst
#18

All right, though a few quarters back, as you're aware, quite a bit of competition was entering around Asian products, and as you know, we experienced some volume softness in that area. So has that situation settled down?

Janumahanti Lakshmana Rao executive
#19

Yeah, growth has actually been quite strong for us this quarter. In Q4 versus Q4, we're seeing over 17% growth coming out of Asian pains, so that represents a really solid recovery on our side. All right.

Richa Agarwal analyst
#20

All right, could you go into more detail on the reason for the lubricant segment’s very steep drop? I’m not certain how that squares with the industry, since typically industry growth, you know, usually falls somewhere in the range of minus 2 to plus 2. This looks like a steeper decrease than that. So are we losing customers from additional there?

Janumahanti Lakshmana Rao executive
#21

Right, we did lose a client, BPCL, near the close of the last financial year, and that client used to bring in a significant amount of sales. But with the tendering system and the public sector, they go strictly by L1. We weren't able to match their pricing, so we let it go. That's one reason why over the last four quarters we still have a loss in sales — last year alone, more than 14, 15 crores of turnover came from BPCL, and that has gone away this full year.

Richa Agarwal analyst
#22

Alright.

Janumahanti Lakshmana Rao executive
#23

That's part of why loop sales went down.

Richa Agarwal analyst
#24

All right. So on the capacity side, how much more capacity are we aiming for at Braston, and for Pharma too? Because within that segment we do have some capacity capex planned.

Janumahanti Lakshmana Rao executive
#25

So right now, Pharma is at roughly 1500 tons, hardly more than that, and we still need to put new investments into that segment to bring it up to 2,500 tons this year. And with Grassium, we've already built capacity of more than 12,000 tons. That's 5,000 at Panipat, 4,400 at Church, and about 2,500 at Mahad, which comes through Satara. So altogether 12,000 tonnes of capacity has been created, and it's running at around 65% capacity as of now. The utilization as of now, which was better than last year, when it was in the 50s. So one of the reasons for the better performance is that those plants are now running at least in the 60, 65% range of capacity utilization. And as we move forward and demand also picks up, the plant capacity utilization will improve there as well.

Richa Agarwal analyst
#26

Alright. Alright. So one month has already gone by in the first quarter. And do you have any idea what Syntax sales might look like, given the impact on ice cream sales? Are you seeing growth this quarter?

Janumahanti Lakshmana Rao executive
#27

Right, I’m not able to say much regarding this quarter, though April has been quite strong, and we’ve observed momentum across the board despite the West Asia war, which has affected overall sentiment. Still, consumption of items such as ice creams or curds won’t be hit, since these aren’t luxury goods. And with paint as well, we’re seeing solid momentum even during April.

Richa Agarwal analyst
#28

Alright, thanks a lot. I’ll return to this later.

Janumahanti Lakshmana Rao executive
#29

Yeah.

Operator operator
#30

Thank you. Our next question comes from Chiral at Keynote Capitals. Your line is open. Could you please use the handset when speaking?

Chirag Maroo analyst
#31

Hello there. Can you hear me at this point?

Operator operator
#32

I appreciate that.

Chirag Maroo analyst
#33

Yes. Congratulations, Daxman sir, on a great set of numbers. My first question has to do with understanding what Vinyas said about expanding capacity from the current 62,000 MPa. What are we looking at for next year? Because right now we are already hitting 100 or 70 percentage capacity utilization.

Janumahanti Lakshmana Rao executive
#34

So our capacity stands at 63,000 tons, while utilization is barely 43,000. That means there's still a considerable distance to cover before we fully use that capacity. A few of the machines ordered last year will be arriving during this year, since there's always some replacement of aging equipment along with modest expansion — particularly at units such as Mansour and Satara, where Mahad especially represents growth areas, and Pharma will keep adding machinery to satisfy rising demand for our products. So those are the three areas. However, we have a notably smaller capital investment budget for this current financial year — it was 140 crores two years back, sustained across two consecutive years, and 120 crores in this financial year 2526. We expect to hold this capex to 8085 crores next year, that is 2627. Going forward, we will pursue only brownfield expansions.

Chirag Maroo analyst
#35

Understood, understood. And by the close of FY27, that gets us to roughly 70,000 MPK capacity, right? Am I correct in that assumption?

Janumahanti Lakshmana Rao executive
#36

Yeah, I think we should land close to 68, 67. In Pharma, capacity-wise, the tonnage won't be all that large — it may be 1,200 tons. And the brownfield expansions are just the new saves at Mysore and Satara. Satara is essentially the supply for the Mahad plant. So those are the two areas, along with the rest of the plants we're looking at, and of course the north plant Paripat, where thin wall capacities are being added. Four missions are coming this July. So by the end of this financial year — that is, 2627 — it will probably be somewhere around 67, 68,000, maybe close to $70,000.

Chirag Maroo analyst
#37

Understood. Understood. So my second question is, generally, whenever significant fluctuation in raw material prices occurs, the players operating in the low-margin packaging industry run into a lot of headwinds, and at those times clients tend to shift to different layers within the industry. We just wanted to get a sense of this current situation, which is going on because of the war. Has it led to some older clients who went away from us, or some new clients being added to our portfolio?

Janumahanti Lakshmana Rao executive
#38

Actually, the opposite of what you might expect is happening. What we're actually seeing is clients returning to us in droves, since they're concerned about connectivity, their capacity to procure materials, and how quickly they can respond to the international situation. So we saw a spike in call ups even from long-standing customers such as Berger and Naralak, who previously placed orders with us for just a handful of grades and are now raising their call ups out of worry — rather, I'd say, out of concern over supply chain disruptions at smaller firms. So they're coming back to us with larger volumes, and we should also recognize that the relationship between our clients and us has grown stronger because the external environment is fragile. So in fact we're seeing a number of them return to us. And reliance on companies such as Maltech is set to rise, because naturally I don't view that as an advantage, but the situation is such that materials at times in March in particular became extremely hard to source. Yet thanks to our long-term relationship with Reliance and our other suppliers in oil and hml, we were able to secure the needed material on time.

Chirag Maroo analyst
#39

Understood. And sir, would it be fair to ask — although you noted in the press release that we're able to pass through all of the cost increases — I just wanted to get a read on the current situation: is it fair to assume that you can hold gross margins at the 46, 47 percentage level in the quarters ahead as well?

Janumahanti Lakshmana Rao executive
#40

Of course, we've handed the full price increase over to customers in every segment, and they've also shown appreciation for the actual circumstances on the ground—some of them have even shortened how often raw material prices get adjusted. What that means is that previously adjustments happened quarterly, and now they've moved to a monthly basis or sometimes even a correction every 15 days. So in that way, when prices fall, we'll likewise need to pass the decrease along to them. It's a fair arrangement. Still, I'm extremely grateful to all our customers. Most of them accepted the price increase quickly, since the movement in March was so swift. It started at 105 rupees and climbed to 160, and at present it's hovering around 145, 150. So we're in this sort of situation, and we've found our customers very much with us, and I believe we can keep maintaining our trust profit margins.

Chirag Maroo analyst
#41

Glad to hear that, sir. So on the capital allocation side — you mentioned that this year we'd be putting less toward spending or expanding our capacity — would it be fair to assume that the extra 4050 crore we're earning will go toward paying down debt?

Janumahanti Lakshmana Rao executive
#42

I'll go ahead and start with the implementation of—

Chirag Maroo analyst
#43

On the debt repayment question — yes, as a result of the capacity expansion, we've taken on some debt onto the books.

Janumahanti Lakshmana Rao executive
#44

Right, so that payment comes out of the cash accruals — though it’s next year. You mean next year’s capital asset.

Chirag Maroo analyst
#45

Yeah. Correct. That’s for FY27. Yes, sir.

Janumahanti Lakshmana Rao executive
#46

Yeah. Our plan is that it will land somewhere around 80 to 80 ficros. On the whole, that could come mostly from internal accruals. A little bit here and there from debt if it's needed.

Chirag Maroo analyst
#47

We're going to need to take on debt.

Janumahanti Lakshmana Rao executive
#48

We expect cash generation to come in well above 80 crores. On the share side itself, when you look at cash generation, it's roughly 72 plus 59123 crores of depreciation. What I mean is, we may have paid out a dividend of about 20 crores. Even so, our net cash accruals are still 100 crores. So we should be able to meet that within what we need for next year. The cash flow,

Chirag Maroo analyst
#49

There's more borrowing tied to that capacity, and I'm just trying to get my head around it.

Janumahanti Lakshmana Rao executive
#50

There's a chance it might be temporary in nature, but on the whole, I don't expect debt to go up.

Chirag Maroo analyst
#51

Okay, so just one final question and then I’ll rejoin the queue. There’s a single accounting point I’d like to clarify for this quarter specifically. We saw a notable increase in other expenses. Would you be able to explain what’s driving that?

Janumahanti Lakshmana Rao executive
#52

What about the other expenses?

Chirag Maroo analyst
#53

Yes, sir.

Janumahanti Lakshmana Rao executive
#54

Yes. A few factors are involved: we've undertaken significant preventive maintenance, replacing screws and certain other machine components so they're compatible with the RCP edition. Recycled plastic is now a requirement—30% is mandatory at present, and starting next April that figure rises to 40%. Machines fitted with standard screws simply can't handle a mix like that, so we've moved to stronger screw materials and screw systems from a technical standpoint, and we managed to complete those corrections to a fair degree during this quarter. It's therefore a one-time expansion and maintenance expense of a preventive kind, though it has been recorded in the P and L.

Chirag Maroo analyst
#55

So that RTP requirement you mentioned is compulsory, correct? And it applies only to the paint and lube segment, is that right?

Janumahanti Lakshmana Rao executive
#56

Right now, yes—pharma and food are exempt from this. But the paint loop makes up, you know, the majority of our sales. So when you look at volume, that's the reason we need to be prepared for those to be appropriately modified.

Chirag Maroo analyst
#57

Thanks a lot, sir — I'll hand it back over to you.

Operator operator
#58

Thanks. Our next question comes from Sandeep Modi, an individual investor, so please go ahead.

Sandeep Modi unknown
#59

Yes, sir. You can hear me now.

Janumahanti Lakshmana Rao executive
#60

Yeah,

Sandeep Modi unknown
#61

Yeah. Sir, first off, congratulations to the management for raising the stake from 33.07 to 33.19.

Janumahanti Lakshmana Rao executive
#62

Alright.

Sandeep Modi unknown
#63

And sir, one more thing. How many pharma companies have visited our premises? Any good news about pharma business, status of new product etc?

Janumahanti Lakshmana Rao executive
#64

Sanjay, you’ll be quite pleased to hear that during year one itself — or let me put it as the first year of full operations — we achieved growth of 210% versus the prior year. Right. 11. 11 and a half crores to nearly 34 crores. 10.7 to 34.3. That works out to a 219% rise in pharmaceuticals. Naturally the base is small, so I’d still count it as a solid jump, particularly given how competitive pharma packaging is. Thanks to our strong product range and our capacity to develop new packs more quickly, we’ve been able to entrench ourselves in this field and become a recognized name in the industry fast. So we’ve now again set a 50% increase as our target for the current year. That means reaching roughly 5254 crores in the next financial year. Quite a few clients are visiting these days. I’ve lost count. And several of them are at different stages. Some are purchasing commercially, some are in line trial. Some are in the process of establishing the RPACs and so on. And some two, three new products, different cap systems are being introduced. As I mentioned, we’re also exploring ophthalmic novel sprays along with a couple of other products that I can’t disclose today since they’re at a nascent stage of discussion.

Janumahanti Lakshmana Rao executive
#65

But rest assured, we will keep broadening the range of products we offer each year, and in the years ahead we’ll go further and further into the pharma sector.

Sandeep Modi unknown
#66

Yes sir. Anyway sir, how many new products are in process now? Molds are in process in pharma.

Janumahanti Lakshmana Rao executive
#67

Now, molds — that part I can't simply give you a number for. At any point it might be 5 or 10 molds. It could involve new bottles, new sizes, or the same sizes at different weights. So in that way, different courses and different cavities might get changed, or a completely new group of products is being developed. So at any moment, you could say five to ten products will be in play each quarter.

Sandeep Modi unknown
#68

All right? All right. Yes, sir. Just one. One additional item. There’s no margin available in exchange for molted packaging set. Could you provide a few details on that?

Janumahanti Lakshmana Rao executive
#69

Oh, I’m not really familiar with the stock exchange and their loans.

Sandeep Modi unknown
#70

We had been pledging those shares and receiving margin against them. And then all at once the exchanges halted that. So sir, kindly look into this matter and review it. And sir, what's the status of the land we purchased? Is any expansion underway there?

Janumahanti Lakshmana Rao executive
#71

Right, right. So the land has only just been acquired, but various bureaucratic matters meant they had to hand it over. At this point the land is at the year mark. The road out front of the property is being laid right now, since it sits in front of our Sultanpur unit. So we genuinely see it each day. We should probably be able to secure the position or agreement within this month, and after that we'll be in a position to begin commercial construction. That's among the reasons construction activity also wasn't able to get started.

Sandeep Modi unknown
#72

Yeah, so there was pharma packaging. We're trying to get some new — this thing — started.

Janumahanti Lakshmana Rao executive
#73

Right, so this new plant — this new land — is primarily intended for pharma only.

Sandeep Modi unknown
#74

Alright.

Janumahanti Lakshmana Rao executive
#75

Work on the construction is going to get underway right away.

Sandeep Modi unknown
#76

And when does that new factory come online — when will it be finished?

Janumahanti Lakshmana Rao executive
#77

My sense is that commercial production won’t begin until the start of the next financial year. In other words, in the next calendar year—construction could take at least 8 or 9 months to finish. Once the land is handed over, for various reasons there’s a delay from the industrial estate in handing over that land. We paid for it more than seven or eight months ago.

Sandeep Modi unknown
#78

So it should be fully up and running around 2028.

Janumahanti Lakshmana Rao executive
#79

Yes, 2727. I think we might get the new plant started before this financial year wraps up, given the holdup with the land allotment. If that hadn't happened, it would have been done in Q3 of this year.

Sandeep Modi unknown
#80

All right, all right, thank you so much, sir. Appreciate the response.

Operator operator
#81

Thanks. Our next question comes from Deepak Saha at Ashoka Institutional Equities. Go ahead, please.

Janumahanti Lakshmana Rao executive
#82

Correct.

Dipak Saha analyst
#83

Hi, thanks. Appreciate the chance to ask. Well, first off, congrats on those results. I've just got one housekeeping question. Could you share the IML versus non-IML breakdown for Four Key and 526?

Janumahanti Lakshmana Rao executive
#84

For the 4Q, it was roughly 75.5%, and overall here it's 75.1%. So in value terms, that comes to 76.8%. So you could say nearly 77% sits within IML.

Dipak Saha analyst
#85

Understood, that helps. I joined a bit late, so forgive me if I missed this. Regarding paid volume, we saw meaningful growth this quarter. Was there anything one-off in there? Because for 4Q, this sort of pain growth in volume — roughly 26% YY growth — is something we haven't seen in quite a while. So if you could share some color on whether that's sustainable going forward and what drove that kind of growth.

Janumahanti Lakshmana Rao executive
#86

Oh, 26% volume growth. I didn't say it's 14.4% in value terms, and 13.5% is a gross in the paint segment. That 60%. What I said is the ABG numbers for the quarter — this particular quarter, ABG compared to the previous year Q4 — the ABG numbers have shot up by 60%.

Dipak Saha analyst
#87

And nobody else is there,

Janumahanti Lakshmana Rao executive
#88

Apologies,

Dipak Saha analyst
#89

Nobody is up in the morning.

Janumahanti Lakshmana Rao executive
#90

I couldn't quite hear you clearly.

Dipak Saha analyst
#91

There isn't any one-time factor behind the volume growth we're seeing. There's really no one-off item like that, correct?

Janumahanti Lakshmana Rao executive
#92

No. What you're saying is this is one of those occasions, and it won't even happen again.

Dipak Saha analyst
#93

Yeah, yeah, yeah.

Janumahanti Lakshmana Rao executive
#94

Growth has been steady in that 40 to 60% range, and that's the yearly figure overall. For the quarter, quarter-over-quarter growth came in above 60%, and the yearly number is also near 60%. So each quarter shows consistent growth. That may be because they're picking up additional share in the paint segment as well. My sense is this will keep going. Still, given how aggressively they're marketing and how aggressively they're expanding production capacity, I think we'll definitely see strong double digits over the next couple of years.

Dipak Saha analyst
#95

When we look at the full year 27, how do we make sense of the growth figures? And if you could give us a rough breakdown, that would help, since lubricants have been shrinking while paint has begun to expand. You mentioned that both Kishing Paints and other players have been growing lately. So if you could shed some light on a full year basis for FY27, what volume growth should we expect, and how would that split up?

Janumahanti Lakshmana Rao executive
#96

Look, I think there are two ways to view this going forward. Since volume growth is driven by plain kilograms, then for pharma, even at 50% growth, the number of kgs added will be smaller. However, in rupee terms or by value, it will be significantly larger. That's because our average realization in pharma is nearly twice what it is in the other segments. So purely on volume, it could appear to be 10 to 15%. A growth rate anywhere in the 10 to 15% range is achievable. But value-wise, I'm confident we'll be posting value growth of between 13 to 15%, similar to what we achieved this year, 13.3%. Our expectation is that we'll land somewhere in the 13 to 15% range for value growth in the coming financial year. That's the reason I mentioned that in the year 2627 we may go past the 1000 floor mark in sales.

Dipak Saha analyst
#97

Understood — that’s genuinely useful. Thanks very much. And best of luck.

Janumahanti Lakshmana Rao executive
#98

Thanks.

Operator operator
#99

Thanks. Our following question comes from Ranav Darshita at DSP Asset Managers. You have the floor.

Darshita Shah analyst
#100

Thanks for giving me the chance. My first question concerns the growth in paints. I believe the earlier participant said paints volume growth came in at 26%. I think that figure is for the fourth quarter. If you could just help us understand where this growth has come from. I understand you’ve said that a bigger portion of the growth has come from abg, but have Berger and Naruto also contributed meaningfully to this particular growth? You know, and that’s because of the raw material unavailability issue.

Janumahanti Lakshmana Rao executive
#101

And Narlac only began in March. That's when the actual conflict broke out and things became fragile. So growth from Bedjar and Nairola really only covers a couple of weeks in March, or the final 15 days of March. Sure, they were purchasing from us, but from March onward the figures improved. Asian Paints and ABG kept growing steadily. You know, Asian Paints was negative during the third quarter, yet in the fourth quarter there's a solid positive increase of 17%, which brought the overall figure back into positive territory for the full year. And ABG contributed heavily to that 14% growth in the paint segment. By adding substantially, close to 10% of the growth came from — I mean ABG by itself — with the remaining 4% coming from Asian Paints and others.

Darshita Shah analyst
#102

Understood. Second, we’ve noted that customers have absorbed a bigger share of the rise in raw material prices. For the fourth quarter, our volume growth came in at 17%, and our top line growth was also 17%. Ideally, if there had also been some realization growth, which I’m assuming would have occurred in March, we should have seen stronger value growth, since there was volume and there could be some realization growth too. So is it reasonable to expect that a larger portion of the value growth will show up in the first quarter, and that realization-related growth will appear in the first quarter?

Janumahanti Lakshmana Rao executive
#103

Yes, your guess is correct, because only during the final 2 weeks of March did we get the price increase, since the war broke out on 1st of March. So obviously we had to hold pricing steady until the middle of March, and in some cases until 25th of March. So that's hardly a week. The price reflects the high price. But you'll notice that more significantly in Q1.

Darshita Shah analyst
#104

Understood. And since we’ve been raising prices, I’d assume our raw material polypropylene has increased by at least 25% to 30%, roughly. Have we lost any customers? Given that we might be revising prices more frequently than our usual practice — I’m guessing every 15 days or one month or so — have we lost any customers because of that?

Janumahanti Lakshmana Rao executive
#105

You see, every one of our customers is a blue chip company within its own Segment — whether that's ice creams, curds, paint, or food oils. So cutting back their market presence isn't something they can afford to do. They're continuing to make their products at the same pace as of today. I don't know how bad it is. It can get worse, it can. But right now, we aren't seeing any demand downturn among any of our top clients. So that's a very reassuring fact, and it's one we're observing too. And very rarely, out of our 100%, hardly 4 to 5% or at most 6, 7% of our sales would go to, I mean, non blue chip clients. So our impact efedding could happen in those 5,6% to the tune of 1,2%. But while we lose 1,2% of such business, our major clients, Asian Paints and ABG or even HUL, they're all going in full guns. Their demand increase because it's mainly meant for local consumption. And in pharma obviously the replacement demand, we are replacing others due to our better quality and consistency. That is how we are penetrating in the Indian pharma industry which is meant for exports. But the penetration is mainly into the replacement demand and growing demand for pharma.

Janumahanti Lakshmana Rao executive
#106

You're also probably seeing that every sanction on pharma exports has been entirely lifted, at least for the moment. So the pharma companies are going full steam ahead. They're moving forward with their expansion plans. As a result, we don't expect any immediate impact unless fresh sanctions get imposed on pharma exports. Given that situation, in most cases — 99%, or 98 to 99%, of our clients — they're safe, and they're growing along with domestic demand growth, which is roughly 6 to 8%. You're aware of that. So in that respect, we're safe. And thanks to replacement demand in pharma and other segments, plus more and more AML absorption coming from Asian pains, we're confident we can sustain the growth.

Darshita Shah analyst
#107

Understood. Third, regarding growth in the FMCG or FNF segment, how ought we to think about that? To be specific, just the fnf growth from FY27 for the year — FY27 and beyond. From the Panipat facility, we had onboarded a few customers. I believe we added a few more customers in 4Q. If you could shed some light on what capacity utilization at the Panipat plant for FMCG was in third quarter and what it was in fourth quarter, and how do you think about this in FY27?

Janumahanti Lakshmana Rao executive
#108

I didn't have exact figures, but my sense is that Q3 contributed almost nothing, since that's when we began Panipat thinwall production. Q4, though, opened with respectable volumes — roughly a couple of crores in turnover came in during March alone from QPAK and Tinwal combined — and those numbers are climbing. On the client side, we recently signed a couple of large customers who had been purchasing from our competitors in that region, and that will definitely make a meaningful addition to the figures in the next financial year. So for food and FMCG, if you look at thin wall by itself, it's 15.4%. Including thick wall as well, food comes to about 18%. For that 15.4, I'm confident we'll see at least 20% growth — growth in food and FMCG, including the north numbers, for the next financial year.

Darshita Shah analyst
#109

Understood. Could you also shed some light on the peak revenue potential from the Panipat facilities that we should be thinking about, and how long it will take us to get to peak capacity utilization there?

Janumahanti Lakshmana Rao executive
#110

Looking at the ABG plant, which is primarily for pails, and at QPAC, in Panipat we're barely hitting about 60% capacity utilization. In thin wall, which is only about four or five months old, we're probably at around 70%, 25% capacity utilization. So there's a long way to go. In fact, we're adding four more machines in July for Thinwal. That will expand capacity by another 100%, and next year even if we reach 50% capacity utilization, that will add handsomely to the numbers. So Paripat has a long way to go, and the building is completely ready. Now the second building, for food and FMCG, has four machines, and that will be eight from July. So we're getting ready for the festive season, which starts sometime in July. So I think next year there will be a good jump. I don't think it will go to 80% capacity, but at least from the current 20% it may go up to 40, 50% on a bigger capacity.

Darshita Shah analyst
#111

Alright. And finally, thank you.

Operator operator
#112

Ma’. Am, sorry to interrupt. If I could ask you, please come back.

Darshita Shah analyst
#113

Sure.

Operator operator
#114

Thank you. One request for everyone on the call: please keep yourself to one question per participant, then get back in the queue if you have a follow-up. Our next question comes from Akhil Parekh at 361 Capital. Go ahead.

Akhil Parekh analyst
#115

Yes, thanks for the chance to ask a question, and congratulations to you, sir, on such a strong set of numbers. My first question concerns EBITDA per kg — we've shown solid improvement there. What should that figure look like in FY27 and 28, say?

Janumahanti Lakshmana Rao executive
#116

For FY27, as I expected, we're targeting at least 42 to 43. A figure of 42.5 might be a solid estimate for the full year. Then, regarding how it shapes up in Pharma Q In 28, we can probably aim for around the 43 to 44 range. So the uptrend will definitely continue now, for two reasons. It's not only growth across the different segments, but also the consolidation of our operations in Hyderabad, where we cut five plants down to two. Right now only Anaram and Sultanpur remain as the two units, and they produce everything that was previously made across five plants, which brings better efficiencies. There's more headcount reduction, and movement of goods has declined. All of this is translating into better productivity. This consolidation only happened through January of this year — meaning up to January. So the full benefit of this consolidation and the improved efficiencies should show up in the next financial year. That alone ought to add a rupee or so on top of the 40.7 we achieved this year, versus 37.6 the prior year. So that's a jump of 8%, an 8.4% increase in the EBITDA margin — a substantial jump, which we recovered over the last couple of years, and going forward, with these efficiencies kicking in, more and more HCL labels also being made in house, and the new automation approaches we've taken up in various areas to reduce manpower dependency, efficiencies are going to improve going forward.

Janumahanti Lakshmana Rao executive
#117

And even today, ABG plants are running at barely about 60% capacity, and my hope is that next year they'll hit 70-plus, which would be a very good thing for the bottom line. So going forward, with only the brownfield expansions, which may need marginal capital, the rise in capacity utilization will kick in. So I view 26 and 27 very positively, and to target at least the 42.5 to 243 range for 26, 27, 27, 28 — maybe a little hard to predict right now. Perhaps we could even touch 45 with a good wind in pharma. If that happens, we might aim at 44, 45 as well for the next 37, 28, but I can give a clearer picture going forward over the next couple of quarters.

Akhil Parekh analyst
#118

Thanks, sir. And to double-check the guidance you gave for 27: you mentioned volume growth of 10 to 15% and value growth of 13 to 13 to 15%. Did I get that right?

Janumahanti Lakshmana Rao executive
#119

Yes, 10 to 13%. That's because pharma won't be adding volume. It'll barely show up in a handful of terms. So even the rupees go up by 50%. Last year, what was it barely — how much? 853 tons. So last year it was 853 tons. And then the following year, 2627, it will hardly reach 1200 to 1300 kgs. Sorry — tons, 1200 to 1300 tons, even if you get a 50% increase. So on volume, the increment might look like 10 to 13%. But on value, the increment we're targeting is 13 to 15%.

Akhil Parekh analyst
#120

All right, all right. So with that implant, we should comfortably exceed 1200 crore in revenue by 598 — that was the earlier guidance, as I recall.

Janumahanti Lakshmana Rao executive
#121

I certainly hope that's the case. Still, I'm confident that for this year we're definitely targeting 1,000 plus.

Operator operator
#122

Thanks. Akhil, I'd like to come back with a follow-up question. Participants, please keep your questions limited. Our next question comes from Deepak at Sundaram Mutual Fund. Go ahead.

Deepak Kumar analyst
#123

Yes, thanks for giving me the chance. Can you hear me okay?

Janumahanti Lakshmana Rao executive
#124

Yes.

Deepak Kumar analyst
#125

Sir, my first question concerned paint. So, doing a quick back-of-the-envelope calculation, even the non-ABG paint volumes in Q4 would have risen by approximately 13 to 15%, which had been, shall we say, a declining or rather flattish trend during the first nine months. So I just wanted to get a sense of what changed this quarter, since you did point out that one change was IML adoption by Asian Paints. So I just wanted to understand how sustainable that double-digit volume growth in non-ABG, which you saw in Q4, actually is, and what the volume growth outlook is for non-ABG clients in FY27?

Janumahanti Lakshmana Rao executive
#126

Yes. You mentioned that the reason why Asian Credits and an increasing number of brands are adopting IML is among the factors behind us winning back their larger volume of business. And I hope that will keep going, because their artworks are extremely critical. If you look at them in the market, they have metallic IML, which is top-class IML to handle both technically and visually. So visually it delivers an excellent appearance, and technically it is very complex to handle. So I don't think we will lose that edge over the next 2 years, and we may keep gaining traction with Asian Paints given their commitment. Because we are on their commitment, we invested in several new initiatives in printing and even in robotics. So and they generally respect their commitment very much. So I still look at double-digit growth formation paints in the years to come.

Deepak Kumar analyst
#127

Understood. And sir, as you pointed out earlier, because of the prestige issue and the sharp inflation in polymer prices, we were able to put through some price increases. Could you specify how much of a price hike has been implemented compared with, you know, the steep rise in raw material costs?

Janumahanti Lakshmana Rao executive
#128

We are fully offsetting the raw material price increase. It isn’t a fixed percentage—whatever price hike they’ve passed through in their pricing, they raise prices accordingly.

Operator operator
#129

Thanks, Deepak. I’d like to return for one more follow-up question. Our next question comes from Shirish Pradeshi at Motila Loswan. Please go ahead.

Shirish Pardeshi analyst
#130

Good evening, sir, and thank you for the chance to speak and for the congratulations. My question is specifically about the paints. If we've reported a 42.1% EBITDA per kg, how has the paint EBITDA moved over yui

Janumahanti Lakshmana Rao executive
#131

You know, I keep telling you—look at EBITDA pace and square packs. EBITDA sits somewhere around 30 to 35 per kg, and what lifts it is food and FMCG plus pharma, that overall average. So that's it. I don't have a detailed breakdown, I mean, of EBITDA per kg for each segment, but it'll fall in the range of 30 to 33.

Shirish Pardeshi analyst
#132

The reason I'm asking is that, as you mentioned, we've already passed along those price increases. So despite ABGs rising more than 60%, will EBITDA per kg in FY27 show an upward path, or will it stay in that same range?

Janumahanti Lakshmana Rao executive
#133

That will certainly stay positive across all our clients, and especially for ABG, since with ABC we are now setting up Mahad during this year, and those figures will continue to improve substantially. So for next year as well, we anticipate strong growth in the paint segment.

Shirish Pardeshi analyst
#134

Alright. On that final question about food and FMCG, I think it comes down to the mix as new clients arrive, and you mentioned that existing clients are also growing their business. So how should we view food, FMCG, and the count of clients we've added — will that number go beyond FY26, or stay at a similar level, or in terms of growth, and on margin, if you could offer some qualitative comments.

Janumahanti Lakshmana Rao executive
#135

I’m quite sure that a growing number of clients will be added in 2627 compared with last year. The main reason is that operations at our north plant began in October and November, and traction is gradually building. As I mentioned, in March we made sales of roughly three and a half crores for the Q pack and food combined, whereas that figure was zero a year earlier. So looking ahead, that in itself signals that 4235 to 40 crores of new addition business can come from the north in QPAC and food combined. That still leaves capacity utilization below 50%, but it will be a handsome number of new additions. So in my view, 2627 will see many more plant editions in food and FMCG from the north than the overall year 2526.

Operator operator
#136

Thank you. Actually, I’d like to ask to come back for a follow-up question. The next question comes from Raj at Fiber and <<inaudible>> Asset Management. Please go ahead.

Analyst analyst
#137

Thanks for giving me the chance to ask. Regarding the volume growth you mentioned for 2627, roughly 13 to 15% — so what I mean is, if you're saying ABG ought to grow at around double digit plus, sorry, Ocean Paints would go at double digits, and ABG is growing much faster for us, plus food and SMCG, I think those volumes are running at 20 to 25%. So I just wanted to get a sense of where the disconnect lies. I mean, if that kind of growth is what we can see, then FY27 ideally should be much better for us in terms of volumes. So I just wanted to understand. No,

Janumahanti Lakshmana Rao executive
#138

What I actually said was that volumes would rise 10 to 13%, not 10 to 15%, since pharma volumes measured in tonnes will come in lower. And for value, I gave 13 to 15%. That said, Loops is one segment where we don't expect much of an increase even over the coming 2 years, because it's stagnating. The market and the industry themselves aren't expanding — growth there is only in single digits, and at times not even that. So that segment accounts for a substantial 17, 18% of our turnover. Therefore, I'm not expecting any meaningful growth from that segment. A couple of points of growth may come in Castrol, but I don't see lube lifting us. So what lifts us is Asian pains under ABG, as you correctly pointed out, because of Asian pains growth even in this full year. If you look at it, though Q4 was 17%, for the full year it's hardly around 33 and a half percent. So that 3 becoming 10 will be a good value add for us in the year 2627. We foresee that for that, and loop being a laggard. That's why we're targeting between 10 to 13% volume growth.

Analyst analyst
#139

If we treat that as a steady state — I mean, the portion of raw material price increases — our realizations in paints have been roughly flat. But now that Asian Paints is also raising its IML consumption, and we're at a different scale for ABV as well, do we see realizations getting better, or our pricing power getting better, because of IML in paints, relative to the price increase we take due to raw material inflation?

Janumahanti Lakshmana Rao executive
#140

Right, so that's the reason I feel good about where EBITDA growth is headed — from the 40.7 we delivered this year up to a 42.5 level. It might come in a bit better than that. We'll just have to watch how the war and the other economic factors shake out.

Operator operator
#141

Thanks, Raj. I’d like to come back for one more follow-up question. Our next question comes from Pard Gohel at Omtara, on the line. Please go ahead.

Parth Gohil analyst
#142

Congrats to the team and to all of management on these results. Sir, my question relates to the lubricants segment. Do we further expect or foresee any volume loss in the quarters ahead? Or would it be fair to say things have normalized at this point?

Janumahanti Lakshmana Rao executive
#143

Yeah, I think that's a really smart question. Actually, I'm also of the view that it will remain there, since we have no further public sector units left to lose. And every private sector company appreciates our relationship, our quality, and the consistency, which matters a great deal. I'm not claiming that isn't the case for the public sector, but the public sector places more value on pricing than on anything else. And that's their policy. And now that all the PSU business has been lost, we may hold steady at the present levels in loops.

Parth Gohil analyst
#144

All right, thank you, sir.

Operator operator
#145

Thanks, everyone — one ask before we continue: please keep it to a single question each. Our next follow-up comes from Chirag at Keynote Capitals. Go ahead.

Chirag Maroo analyst
#146

Thanks once more for the chance to speak, sir. I just wanted to get your perspective on the company’s ROC. There was a time when we were a business producing a 20% ROC — that remains our target. Same as before. And second, I’d like to understand: our working capital days have been stretching out. So what’s the outlook there?

Janumahanti Lakshmana Rao executive
#147

Look, operating at this level essentially means you're dealing with an elevated valuation. And that's also because over the past three weeks we've been buying material at a high price, which indirectly may have pushed the value up, and inventory days have gotten a bit longer too, since in pharma you have to keep 3 months of material on hand, because certain requirements usually arrive in batch quantities for pharma, and their pickup times run a little late, plus payment terms are longer as well. The pharma industry has been running on a 90 day to 110 days payment cycle. So that's why you may be seeing data days and inventory days stretched out somewhat. Going back to ROCE, yes, the ROC has jumped by roughly 14%, from 10.2% to 12.4, and it will probably reach around 13 and a half to 14% in the coming financial year, and it stood at 17 18% two, three years back. I agree that was the period when all these greenfield projects got started. Investment has surged over the last three years, and those investments are beginning to pay off now. This year, I'd say they went past 50 to 60, 60% capacity utilization. But from next year on, I'm confident it will be 70 plus, and they will contribute to the bottom line.

Janumahanti Lakshmana Rao executive
#148

So the ROC will likely begin to come in at roughly 15% by 2728.

Operator operator
#149

Thank you. Our next follow-up question comes from BSP Asset Managers. Please go ahead. Rashida, could I ask you to join the line and then ask your question?

Darshita Shah analyst
#150

Yes, apologies, apologies, apologies. I trust you can hear me at this point.

Operator operator
#151

Yes, ma'am.

Darshita Shah analyst
#152

Yes, thanks for giving me another chance to ask. So could you tell us, once the 4 additional units are in at the Funny Part facility, on top of the 8, what the total capacity for FMCG will be?

Janumahanti Lakshmana Rao executive
#153

Right now I believe it's roughly 1200 tons, or 900 to—sorry, 1000 tons. That will rise to 2000 tons. Food and FMC are in there, and we're adding a small amount of QPAC as well, so around 2,000. Including QPAC, it will reach 2,000 to 2,500 tons per annum.

Darshita Shah analyst
#154

Second, from the standpoint of raw material availability, are we running into any problems right now with polypropylene supplies, and how far out are we covered? At this point

Janumahanti Lakshmana Rao executive
#155

We're covered for nearly 2 months now. That's reflected in our inventory days. So that 2 months of coverage exists physically as well. Material availability has gotten better since Alliance began producing on a regular basis from the middle of March, and they're telling us and assuring us there won't be any shortfall. A couple of grades, particularly in pharma, are in somewhat short supply. That's the area we're focusing on.

Operator operator
#156

Thanks. Please return for a follow-up. The next question comes from Sanskar at Iraya Capital. Go ahead, please.

Shanskar Singhal analyst
#157

Hi there. Yes, sir, the majority of what I asked has already been covered. I just hoped to get some clarity regarding the growth outlook, and you've already addressed both volume and value terms. I merely wanted to confirm that, looking ahead, you've guided toward sustaining roughly 20% growth when it comes to profitability at the EBITDA and PAD levels. So is that guidance staying as it is, or might there be either some upside or a downward revision?

Janumahanti Lakshmana Rao executive
#158

I believe we will definitely get there. Our target is a minimum of 210 crores EBITDA for the coming financial year, compared with 173 — that works out to a 20% increase. Given both the growth in business and the improvements and efficiencies we are generating internally, especially through consolidating units, I'm confident we will hit it. And if circumstances cooperate — meaning the war doesn't cause any further harm — we ought to end up doing even better than that expected figure.

Shanskar Singhal analyst
#159

Alright, thanks.

Operator operator
#160

Thanks. The next question comes from the line of people at Sundaram Mutual Fund. Please go ahead.

Deepak Kumar analyst
#161

Thanks for giving me the chance to ask a follow-up. I have just one question about Pinball. When I look at our growth rates, quarter over quarter came in at more than 44%, and even year over year it's a really strong figure at 30%, versus roughly 13% to 15% during the first nine months. So I just want to get a sense — suppose I were to break that growth down between, let's say, your other plants and Panipat, how much of it is being driven by a new SQ addition or by bringing on a new client? I'd just like a bit of color on how that growth breaks out, what's behind such a high number, and how much of it can be sustained going forward.

Janumahanti Lakshmana Rao executive
#162

Within QPAC.

Deepak Kumar analyst
#163

When it comes to thin modes.

Janumahanti Lakshmana Rao executive
#164

Look, that figure isn’t 30% — it’s 15.4% in value terms, or 18% once you count the bulk food packs. So 18% is what we actually delivered in the year 2627, and the reason my conference remarks say it can be better comes down to our Panipat. Extra capacity is being built there, and we’re getting quite a few inquiries from new clients in that northern area and region. We’ve also begun bringing on clients who started purchasing from March onwards in decent numbers, and going forward they will definitely come to appreciate Maltech’s quality and supply service abilities, which they haven’t seen because of our distance over the last few years. So with our presence now in Panipat, I’m sure we’ll be able to bring on a lot many clients in that region, which will contribute to the increased growth in food and fmcg.

Deepak Kumar analyst
#165

All right, so what about the clients we already have, then? Are we actually seeing any growth from them? Or would you say that most of the growth is coming just from the Panipat side?

Janumahanti Lakshmana Rao executive
#166

No, no, no — every one of our clients is growing. Look at Milky Mist, look at Hudson, look at Walco, our quality walls: their numbers are all rising. Whether it's their ice cream or yogurts, whatever products they sell, their figures keep climbing. The only one that's flat is Cadbury 72k. But as for the top brands, every top brand is posting double-digit growth. So that growth is definitely going to accrue to us. Beyond that, the way we can go further is what I'm explaining — through Panipoint.

Deepak Kumar analyst
#167

All right, all right. Give us whatever help you can.

Janumahanti Lakshmana Rao executive
#168

Thanks.

Operator operator
#169

Thank you. Since nobody else has anything to ask, I'll turn the conference back to management for some closing remarks.

Janumahanti Lakshmana Rao executive
#170

I want to thank everyone for taking an interest and making time to join today's conference call. My particular thanks go to Rajesh Kumar of MK for organizing this call, and to the operator, who has conducted it patiently throughout. I also value the interest people have shown in our company, and you can be assured that we are on a good track. We are also looking at more and more product ranges, which may not be very clearly on the drawing board right now, but it will happen during the next 3 to 4/4 in pharma especially. We are also examining efficiencies to improve cost controls, and we have now set up teams of finance and HR Admin at all the units, who will directly monitor and control the cost elements closely. With this new kind of manager outlook and the consolidation of units, I think we are on a strong wicket to perform better in the coming quarters. I also hope peace will prevail soon, and that all the economists, and especially our Indian economy, will catch up with the speed which it is about to catch, about to reach. So thank you all once again, and bye bye. Good evening.

Operator operator
#171

Much appreciated, sir, on behalf of MTA Global Financial Services Ltd. That brings this conference to a close. We’re grateful you joined us, and your lines can be disconnected at this time. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Mold-Tek Packaging Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Mold-Tek Packaging Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.